Ex-Cedil­la CEO Glucks­mann ex­plores ‘new fron­tier’ at Sen­so­ri­um; R&D chief out at Mer­ck women’s health spin­off Organon

Alexan­dra Glucks­mann is al­ways look­ing for “the next fron­tier” in med­i­cine. Af­ter spend­ing most of her ca­reer in ge­net­ic dis­eases, rare dis­eases and on­col­o­gy, her next pur­suit is in men­tal health.

The long­time bio­phar­ma ex­ec­u­tive is the next CEO at Sen­so­ri­um Ther­a­peu­tics, a biotech lever­ag­ing ma­chine learn­ing to de­vel­op new men­tal health treat­ments, start­ing from plant com­po­nents that are known to be psy­choac­tive. The com­pa­ny’s lead pro­gram in anx­i­ety is cur­rent­ly in pre­clin­i­cal test­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER